Ascites is a common complication of cirrhosis. It happens due to the effects of portal hypertension and leads to fluid buildup in your abdomen. Ascites can be treated with medications, procedures, and ...

"Ascites in decompensated cirrhosis is a poor prognostic indicator, with a 50% 2-year survival, worsening significantly to 20% to 50% at 1 year when the ascites becomes refractory to medical therapy." ...

The alfa pump® system received U.S. FDA Premarket Approval in December 2024 for the treatment of recurrent or refractory ascites due to liver cirrhosis. It is the first active implantable medical ...

Abdominal swelling, swelling of hands and feet, shortness of breath, fatigue and weakness are the usual clinical features of a patient with ascites. Infection, causing Spontaneous Bacterial ...

Portal vein thrombosis (PVT) is a critical complication in liver cirrhosis (LC), significantly worsening portal hypertension ...

Splenomegaly resulting from portal hypertension can be caused by cirrhosis, hepatic venous outflow tract obstruction and extrahepatic portal vein obstruction. Both cirrhosis and hepatic venous outflow ...

1. Who is the specialist I should consult when I notice ascites? Ascites is treated by a gastroenterologist who will examine the patient first, and may then redirect the patient to another specialist ...

Cirrhosis, most frequently caused by hepatitis C or alcoholism, was the 12th leading cause of death in the United States in 2000, accounting for more than 25,000 deaths. 1 Ascites is the most common ...

HEPATOMEGALY has long been recognized as a frequent clinical finding in diabetes mellitus, particularly among juvenile diabetic patients. The etiology of the hepatomegaly, however, has remained a ...

Fatty liver disease is sometimes called “silent liver disease” because of the few signs it shows until it has progressed. According to the NHS, one in three may be living with the early signs of fatty ...

The CXCR3 chemokine receptor is such a conceivable metastasis-promoting factor as it is upregulated in ovarian carcinomas 9, 10 and involved in cancer growth and metastasis of other solid cancers. 11, ...

Challenges in developing drugs for pancreatic ductal adenocarcinoma (PDAC) include obtaining metastatic cancer tissue for research and validating biomarkers predicative for personalised therapeutic ...